Co-localization of CD169⁺ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression

References

• Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H-J. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017 Aug 1;28(8):1700–13. doi:10.1093/annonc/mdx308.
   PubMed Web of Science ®Google Scholar
• Sleeman JP. The lymph node pre-metastatic niche. J Mol Med (Berl). 2015 Nov;93(11):1173–1184.
   PubMed Web of Science ®Google Scholar
• Martinez-Pomares L, Gordon S. Antigen presentation the macrophage way. Cell. 2007 Nov 16;131(4):641–643. doi:10.1016/j.cell.2007.10.046.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005 Sep;2(9):e284. doi:10.1371/journal.pmed.0020284.
   PubMed Web of Science ®Google Scholar
• Grotz TE, Jakub JW, Mansfield AS, Goldenstein R, Enninga EAL, Nevala WK, Leontovich AA, Markovic SN. Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncoimmunology. 2015 Aug;4(8):e1026504. doi:10.1080/2162402X.2015.1026504.
   PubMed Web of Science ®Google Scholar
• Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients [Research Support, Non-U.S. Gov’t]. BMC Cancer. 2012;12(1):306. doi:10.1186/1471-2407-12-306.
   PubMedGoogle Scholar
• Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA, et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions [Review]. Int J Dev Biol. 2011;55(7–9):861–867. doi:10.1387/ijdb.113371dl.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity [Review]. Curr Opin Immunol. 2010 Apr;22(2):231–237. doi:10.1016/j.coi.2010.01.009.
   PubMed Web of Science ®Google Scholar
• Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Immunol Res. 2013 Dec;57(1–3):172–184.
   PubMed Web of Science ®Google Scholar
• Asano K, Kikuchi K, Tanaka M. CD169 macrophages regulate immune responses toward particulate materials in the circulating fluid. J Biochem. 2018 Aug 1;164(2):77–85. doi:10.1093/jb/mvy050.
   PubMed Web of Science ®Google Scholar
• Louie DAP, Liao S. Lymph node subcapsular sinus macrophages as the frontline of lymphatic immune defense. Front Immunol. 2019;10:347. doi:10.3389/fimmu.2019.00347.
   PubMed Web of Science ®Google Scholar
• Shaabani N, Duhan V, Khairnar V, Gassa A, Ferrer-Tur R, Häussinger D, Recher M, Zelinskyy G, Liu J, Dittmer U. CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection. Cell Death Dis. 2016 Nov 3;7(11):e2446. doi:10.1038/cddis.2016.350.
   PubMed Web of Science ®Google Scholar
• Muerkoster S, Rocha M, Crocker PR, Schirrmacher V, Umansky V. Sialoadhesin-positive host macrophages play an essential role in graft-versus-leukemia reactivity in mice. Blood. 1999 Jun 15;93(12):4375–4386. doi:10.1182/blood.V93.12.4375.
   PubMed Web of Science ®Google Scholar
• Martinez-Pomares L, Gordon S. CD169+ macrophages at the crossroads of antigen presentation. Trends Immunol. 2012 Feb;33(2):66–70. doi:10.1016/j.it.2011.11.001.
   PubMed Web of Science ®Google Scholar
• Garcia Z, Lemaitre F, van Rooijen N, Albert ML, Levy Y, Schwartz O, Bousso P. Subcapsular sinus macrophages promote NK cell accumulation and activation in response to lymph-borne viral particles. Blood. 2012 Dec 6;120(24):4744–4750. doi:10.1182/blood-2012-02-408179.
   PubMed Web of Science ®Google Scholar
• Asano K, Nabeyama A, Miyake Y, Qiu C-H, Kurita A, Tomura M, Kanagawa O, Fujii S-I, Tanaka M. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011 Jan 28;34(1):85–95. doi:10.1016/j.immuni.2010.12.011.
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Yamaguchi M, Erdenebaatar C, Saito F, Tashiro H, Katabuchi H, Takeya M, Komohara Y. Prognostic significance of CD 169-positive lymph node sinus macrophages in patients with endometrial carcinoma. Cancer Sci. 2016 Jun;107(6):846–852. doi:10.1111/cas.12929.
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Komohara Y, Saito Y, Miyamoto Y, Watanabe M, Baba H, Takeya M. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci. 2013 Sep;104(9):1237–1244. doi:10.1111/cas.12212.
   PubMed Web of Science ®Google Scholar
• Asano T, Ohnishi K, Shiota T, Motoshima T, Sugiyama Y, Yatsuda J, Kamba T, Ishizaka K, Komohara Y. CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis. Cancer Sci. 2018 May;109(5):1723–1730. doi:10.1111/cas.13565.
   PubMed Web of Science ®Google Scholar
• Stromvall K, Sundkvist K, Ljungberg B, Halin Bergström S, Bergh A. Reduced number of CD169 + macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients. Prostate. 2017 Nov;77(15):1468–1477. doi:10.1002/pros.23407.
   PubMed Web of Science ®Google Scholar
• Shiota T, Miyasato Y, Ohnishi K, Yamamoto-Ibusuki M, Yamamoto Y, Iwase H, Takeya M, Komohara Y. The clinical significance of CD169-positive lymph node macrophage in patients with breast cancer. PLoS One. 2016;11(11):e0166680. doi:10.1371/journal.pone.0166680.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019 Apr 15;35(4):588–602.e10. doi:10.1016/j.ccell.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Pico de Coana Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015 Aug;21(8):482–491. doi:10.1016/j.molmed.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Swoboda A, Nanda R. Immune checkpoint blockade for breast cancer. Cancer Treat Res. 2018;173:155–165.
   PubMedGoogle Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108–2121. doi:10.1056/NEJMoa1809615.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022. doi:10.3389/fimmu.2019.02022.
   PubMed Web of Science ®Google Scholar
• Heeren AM, de Boer E, Bleeker MC, Musters RJP, Buist MR, Kenter GG, de Gruijl TD, Jordanova ES. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget. 2015 Oct 20;6(32):32484–32493. doi:10.18632/oncotarget.5398.
   PubMedGoogle Scholar
• Heeren AM, Koster BD, Samuels S, Ferns DM, Chondronasiou D, Kenter GG, Jordanova ES, de Gruijl TD. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. Cancer Immunol Res. 2015 Jan;3(1):48–58. doi:10.1158/2326-6066.CIR-14-0149.
   PubMed Web of Science ®Google Scholar
• Ryden L, Jonsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström A-C, Landberg G, Stål O, Thorstenson S, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer. 2005 Jan;41(2):256–264. doi:10.1016/j.ejca.2004.06.030.
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.. J Natl Cancer Inst. 1996 Nov 6;88(21):1543–1549. doi:10.1093/jnci/88.21.1543.
   PubMedGoogle Scholar
• Chebil G, Bendahl PO, Idvall I, Fernö M. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer–clinical associations and reasons for discrepancies. Acta Oncol. 2003;42(7):719–725. doi:10.1080/02841860310004724.
   PubMed Web of Science ®Google Scholar
• Bergenfelz C, Leandersson K. The generation and identity of human myeloid-derived suppressor cells. Front Oncol. 2020;10:109. doi:10.3389/fonc.2020.00109.
   PubMed Web of Science ®Google Scholar
• Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA et al. Evidence for a role of the PD-1: PD-L1pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013 Mar 15;73(6):1733–1741. doi:10.1158/0008-5472.CAN-12-2384.
   PubMed Web of Science ®Google Scholar
• Strand C, Bak M, Borgquist S, Chebil G, Falck A-K, Fjällskog M-L, Grabau D, Hedenfalk I, Jirström K, Klintman M, et al. The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer. Springerplus. 2013 Dec;2(1):111. doi:10.1186/2193-1801-2-111.
   PubMedGoogle Scholar
• Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res. 2007 Apr 1;13(7):1987–1994. doi:10.1158/1078-0432.CCR-06-1823.
   PubMed Web of Science ®Google Scholar
• Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, Jirström K, Leandersson K. Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res. 2015 Sep 22;17(1):130. doi:10.1186/s13058-015-0640-x.
   PubMedGoogle Scholar
• Benjamin DJ, Berger JO, Johannesson M, et al. Redefine statistical significance. Nat Hum Behav. 2018 Jan;2(1):6–10.
   PubMed Web of Science ®Google Scholar
• Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, Wang J, Yuan F, Sun L, Yu Q, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014 Apr;63(4):395–406. doi:10.1007/s00262-014-1519-x.
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Gao F, et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013 Jun;139(3):667–676.
   PubMed Web of Science ®Google Scholar
• Jones D, Pereira ER, Padera TP. Growth and immune evasion of lymph node metastasis. Front Oncol. 2018;8:36. doi:10.3389/fonc.2018.00036.
   PubMed Web of Science ®Google Scholar
• Chang AY, Bhattacharya N, Mu J, Setiadi AF, Carcamo-Cavazos V, Lee GH, Simons DL, Yadegarynia S, Hemati K, Kapelner A, et al. Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med. 2013 Oct;2(11):242. doi:10.1186/1479-5876-11-242.
   Google Scholar
• Jing W, Guo X, Wang G, Bi Y, Han L, Zhu Q, Qiu C, Tanaka M, Zhao Y. Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. Int Immunopharmacol. 2020 Jan;78:106012. doi:10.1016/j.intimp.2019.106012.
   PubMed Web of Science ®Google Scholar
• Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015 Mar 10;6(7):5449–5464. doi:10.18632/oncotarget.3216.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563–567. doi:10.1038/nature14011.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu Y. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathol Res Pract. 2020 Mar;216(3):152802. doi:10.1016/j.prp.2019.152802.
   PubMed Web of Science ®Google Scholar